Mechanistic studies showed that a c-Abl inhibitor attenuated integrin α5β1–induced YAP tyrosine phosphorylation (154), revealing that the integrin α5β1/c-Abl/YAP pathway may be a potential therapeutic target for early-stage atherosclerosis. The gene discussed is ABL1; the disease is atherosclerosis.